TY - JOUR
T1 - Aerosol delivery of nanoparticles in uniform mannitol carriers formulated by ultrasonic spray freeze drying
AU - D'Addio, Suzanne M.
AU - Chan, John Gar Yan
AU - Kwok, Philip Chi Lip
AU - Benson, Bryan R.
AU - Prud'Homme, Robert K.
AU - Chan, Hak Kim
N1 - Funding Information:
This work made use of the Confocal & Electron Microscopy Core Facility at Princeton University and the authors acknowledge Joe Goodhouse for expert help with confocal microscopy. This work was supported through National Science Foundation and the Australian Academy of Science as part of the East Asia and South Pacific Summer Institutes Fellowship (1015344) and through grants from the Australian Research Council (DP0985367 & 120102778).
PY - 2013/11
Y1 - 2013/11
N2 - Purpose: While most examples of nanoparticle therapeutics have involved parenteral or IV administration, pulmonary delivery is an attractive alternative, especially to target and treat local infections and diseases of the lungs. We describe a successful dry powder formulation which is capable of delivering nanoparticles to the lungs with good aerosolization properties, high loadings of nanoparticles, and limited irreversible aggregation. Methods: Aerosolizable mannitol carrier particles that encapsulate nanoparticles with dense PEG coatings were prepared by a combination of ultrasonic atomization and spray freeze drying. This process was contrasted to particle formation by conventional spray drying. Results: Spray freeze drying a solution of nanoparticles and mannitol (2 wt% solids) resulted in particles with an average diameter of 21 ± 1.7 μm, regardless of the fraction of nanoparticles loaded (0-50% of total solids). Spray freeze dried (SFD) powders with a 50% nanoparticle loading had a fine particle fraction (FPF) of 60%. After formulation in a mannitol matrix, nanoparticles redispersed in water to < 1 μm with hand agitation and to < 250 nm with the aid of sonication. Powder production by spray drying was less successful, with low powder yields and extensive, irreversible aggregation of nanoparticles evident upon rehydration. Conclusions: This study reveals the unique advantages of processing by ultrasonic spray freeze drying to produce aerosol dry powders with controlled properties for the delivery of therapeutic nanoparticles to the lungs.
AB - Purpose: While most examples of nanoparticle therapeutics have involved parenteral or IV administration, pulmonary delivery is an attractive alternative, especially to target and treat local infections and diseases of the lungs. We describe a successful dry powder formulation which is capable of delivering nanoparticles to the lungs with good aerosolization properties, high loadings of nanoparticles, and limited irreversible aggregation. Methods: Aerosolizable mannitol carrier particles that encapsulate nanoparticles with dense PEG coatings were prepared by a combination of ultrasonic atomization and spray freeze drying. This process was contrasted to particle formation by conventional spray drying. Results: Spray freeze drying a solution of nanoparticles and mannitol (2 wt% solids) resulted in particles with an average diameter of 21 ± 1.7 μm, regardless of the fraction of nanoparticles loaded (0-50% of total solids). Spray freeze dried (SFD) powders with a 50% nanoparticle loading had a fine particle fraction (FPF) of 60%. After formulation in a mannitol matrix, nanoparticles redispersed in water to < 1 μm with hand agitation and to < 250 nm with the aid of sonication. Powder production by spray drying was less successful, with low powder yields and extensive, irreversible aggregation of nanoparticles evident upon rehydration. Conclusions: This study reveals the unique advantages of processing by ultrasonic spray freeze drying to produce aerosol dry powders with controlled properties for the delivery of therapeutic nanoparticles to the lungs.
KW - NPAC
KW - drug delivery
KW - nanoparticle aerosol carriers
KW - spray drying
KW - spray freeze drying
UR - http://www.scopus.com/inward/record.url?scp=84886099200&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84886099200&partnerID=8YFLogxK
U2 - 10.1007/s11095-013-1120-6
DO - 10.1007/s11095-013-1120-6
M3 - Article
C2 - 23893019
AN - SCOPUS:84886099200
SN - 0724-8741
VL - 30
SP - 2891
EP - 2901
JO - Pharmaceutical Research
JF - Pharmaceutical Research
IS - 11
ER -